With improved understanding of the biology of differentiated thyroid carcinoma its
management is evolving. The approach to surgery for the primary tumour and elective nodal …

The treatment of differentiated thyroid cancer continues to move away from a 'one size fits
all'approach to a process of tailored therapeutic decision-making that incorporates disease …

Modern use of post-operative radioactive iodine (RAI) treatment for differentiated thyroid
cancer (DTC) should be implemented in line with patients' risk stratification. Although …

Summary background Justification for adjuvant radio‐iodine (I‐131) therapy in differentiated
thyroid cancer (DTC) is purely based on retrospective data. This is true for ablative therapy …

Post‐operative management of differentiated thyroid cancer (DTC) often involves
administration of radioactive iodine (RAI) for remnant ablation or adjuvant therapy. However …

Until recently, the usual treatment for differentiated thyroid cancers (DTC) with a size> 1.0 cm
undisputedly consisted of total or near-total thyroidectomy followed by radioiodine …

Differentiated thyroid cancer (DTC) is the most common endocrine malignancy and the fifth
most common cancer in women. DTC therapy requires a multimodal approach, including …

A remarkable, evidence-based trend toward de-escalation has reformed the practice of
radioactive iodine (RAI) administration for thyroid cancer patients. Updated guidelines have …

Radioactive iodine (RAI) is used in treatment of patients with differentiated papillary and
follicular thyroid cancer. It is typically used after thyroidectomy, both as a means of imaging …

Background Since the last major review of literature on the benefit of I-131 therapy, the
continued debate on postoperative radioiodine treatment (RIT) in differentiated thyroid …